DRTS News and Press, Alpha Tau Medical Ltd. From 05/28/25

JERUSALEM, May 28, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® , today announced that CFO Raphi Levy will present at the Jefferies Global H...

- Interim Jan-2025 results from three trials of Alpha DaRT ® in treating pancreatic cancer shared at prestigious 2025 ASCO GI Symposium and R&D Update Day, showing >90% disease control rate , impressive overall survival in sub-group ...

Global Ship Lease Inc New Class A (GSL) is expected to report $2.27 for Q1 2025 Biolase Inc. (BIOLQ) is expected to report for quarter end 2025-03-31 ViewBix Inc (VBIXD) is expected to report for Q1 2025 8x8 Inc (EGHT) is expected to report $0.01 for Q4 2025 Gaucho Group Hol (VINO...

2025-05-18 18:47:59 ET Alpha Tau Medical Ltd. (DRTS) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 5.65%. The average open to low on the day of earnings was -3.84%. The average open to...

2025-05-18 18:42:59 ET Alpha Tau Medical Ltd. (DRTS) - Following Earnings Price Analysis was done using last 12 quarters historical earnings. Opening Gap Moves The historical opening gap move in DRTS stock price following earnings has averaged ±3.36% , with a median of 2.42%. ...

JERUSALEM, May 12, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS , DRTSW ) ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that Mr. Nadav Kidron, the President, CEO, and Chairman of th...

2025-04-28 09:34:25 ET More on Alpha Tau Medical, Oramed Pharmaceuticals, etc. Oramed announces spinoff of protein drug technology Seeking Alpha’s Quant Rating on Alpha Tau Medical Financial information for Alpha Tau Medical Seeking Alpha’s Quan...

JERUSALEM, April 28, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® , announced today that it has successfully closed a registered direct offe...

Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical PR Newswire Oramed leverages its strategic capital markets expertise to support Alpha Tau's breakthrough cancer therapy technology Accelerating multiple late-st...

JERUSALEM, April 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® , announced today that the FDA has approved an Investigational Device Exemption (IDE) application to initiate a pilot st...